Scarica l'app Stockscreener
7.255
1.29%
-0.095
Precedente Chiudi:
$7.35
Aprire:
$7.3
Volume 24 ore:
2,388
Relative Volume:
0.01
Capitalizzazione di mercato:
$3.83M
Reddito:
-
Utile/perdita netta:
$-5.00M
Rapporto P/E:
-0.0253
EPS:
-286.8504
Flusso di cassa netto:
$-4.43M
1 W Prestazione:
-9.20%
1M Prestazione:
-11.48%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$7.18
$7.3888
Intervallo di 1 settimana:
$7.18
$8.00
Portata 52W:
$6.3829
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Nome
Decoy Therapeutics Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
7.19 | 3.91M | 0 | -5.00M | -4.43M | -286.85 |
VRTX
Vertex Pharmaceuticals Inc
|
456.54 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.00 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.54 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.29 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.97 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard
Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView
Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total common shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Discontinued operations of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Statistics – GETTEX:FP11 - TradingView
Gross profit of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Taxes of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Preferred dividends of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
After tax other income/expense of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted net income available to common stockholders of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Pretax income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-operating income (total) of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Basic earnings per share (basic EPS) of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free float of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Revenue Breakdown – GETTEX:FP11 - TradingView
Number of employees of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics (DCOY) Partners with Quantori to Enhance Anti - GuruFocus
Decoy Therapeutics partners with Quantori on AI peptide platform - Investing.com
Decoy Therapeutics enters collaboration with Quantori - TipRanks
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform – NEWSnet Michigan - michigan.newsnetmedia.com
Google Cloud-funded AI aims up to 100-fold faster antiviral peptide design - Stock Titan
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
Decoy Therapeutics Inc. Earnings and Revenue – MUN:FP11 - TradingView
Decoy Therapeutics Inc Azioni (DCOY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Decoy Therapeutics Inc Azioni (DCOY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):